Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | DS-3201b |
Synonyms | |
Therapy Description |
DS-3201b inhibits EZH1 and EZH2, resulting in decreased H3K27 trimethylation and potentially leading to decreased tumor growth (Blood 2017 130:2073). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DS-3201b | DS-3201|Valemetostat Tosylate | EZH1 inhibitor 3 EZH2 inhibitor 18 | DS-3201b inhibits EZH1 and EZH2, resulting in decreased H3K27 trimethylation and potentially leading to decreased tumor growth (Blood 2017 130:2073, PMID: 30658046). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04703192 | Phase II | DS-3201b | Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 6 |
NCT02732275 | Phase I | DS-3201b | DS-3201b in Participants With Lymphomas | Active, not recruiting | USA | 1 |
NCT03110354 | Phase I | DS-3201b | DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL) | Terminated | USA | 0 |
NCT04842877 | Phase II | DS-3201b | Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma | Recruiting | FRA | BEL | 0 |